Voltage-gated calcium channels provide an alternate route for iron uptake in neuronal cell cultures

被引:59
作者
Gaasch, Julie A.
Geldenhuys, Werner J.
Lockman, Paul R.
Allen, David D.
Van der Schyf, Cornelis J.
机构
[1] Northeastern Ohio Univ Coll Med & Pharm, Dept Pharmaceut Sci, Rootstown, OH 44272 USA
[2] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Amarillo, TX 79106 USA
[3] North West Univ, Dept Pharmaceut Sci, ZA-2520 Potchefstroom, South Africa
关键词
Alzheimer's disease; iron-overload toxicity; neurodegeneration; nimodipine; Parkinson's disease; voltage-gated calcium channels;
D O I
10.1007/s11064-007-9313-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recent studies suggest that iron enters cardiomyocytes via the L-type voltage-gated calcium channel (VGCC). The neuronal VGCC may also provide iron entry. As with calcium, extraneous iron is associated with the pathology and progression of neurodegenerative diseases such as Parkinson's and Alzheimer's disease. VGCCs, ubiquitously expressed, may be an important route of excessive entry for both iron and calcium, contributing to cell toxicity or death. We evaluated the uptake of Ca-45(2+) and (55) Fe2+ into NGF-treated rat PC12, and murine N-2 alpha cells. Iron not only competed with calcium for entry into these cells, but iron uptake (similar to calcium uptake) was inhibited by nimodipine, a specific L-type VGCC blocker, and enhanced by FPL 64176, an L-VGCC activator, in a dose-dependent manner. Taken together, these data suggest that voltage-gated calcium channels are an alternate route for iron entry into neuronal cells under conditions that promote cellular iron overload toxicity.
引用
收藏
页码:1686 / 1693
页数:8
相关论文
共 49 条
[1]   Iron metabolism [J].
Aisen, P ;
Wessling-Resnick, M ;
Leibold, EA .
CURRENT OPINION IN CHEMICAL BIOLOGY, 1999, 3 (02) :200-206
[2]   DEGENERATION OF SUBSTANTIA-NIGRA IN CHRONIC PARKINSONS-DISEASE VISUALIZED BY TRANSCRANIAL COLOR-CODED REAL-TIME SONOGRAPHY [J].
BECKER, G ;
SEUFERT, J ;
BOGDAHN, U ;
REICHMANN, H ;
REINERS, K .
NEUROLOGY, 1995, 45 (01) :182-184
[3]   Disturbance of iron metabolism in Parkinson's disease ultrasonography as a biomarker [J].
Berg, D ;
Hochstrasser, H ;
Schweitzer, KJ ;
Riess, O .
NEUROTOXICITY RESEARCH, 2006, 9 (01) :1-13
[4]   Brain iron pathways and their relevance to Parkinson's disease [J].
Berg, D ;
Gerlach, M ;
Youdim, MBH ;
Double, KL ;
Zecca, L ;
Riederer, P ;
Becker, G .
JOURNAL OF NEUROCHEMISTRY, 2001, 79 (02) :225-236
[5]   Iron: A pathological mediator of Alzheimer disease? [J].
Bishop, GM ;
Robinson, SR ;
Liu, Q ;
Perry, G ;
Atwood, CS ;
Smith, MA .
DEVELOPMENTAL NEUROSCIENCE, 2002, 24 (2-3) :184-187
[6]  
Bradbury MWB, 1997, J NEUROCHEM, V69, P443
[7]  
Calderón FH, 1999, J NEUROSCI RES, V56, P620
[8]  
CARLSON RO, 1994, J NEUROSCI, V14, P2272
[9]   Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin? [J].
Castellani, RJ ;
Smith, MA ;
Nunomura, A ;
Harris, PLR ;
Perry, G .
FREE RADICAL BIOLOGY AND MEDICINE, 1999, 26 (11-12) :1508-1512
[10]   CELLULAR-DISTRIBUTION OF TRANSFERRIN, FERRITIN, AND IRON IN NORMAL AND AGED HUMAN BRAINS [J].
CONNOR, JR ;
MENZIES, SL ;
STMARTIN, SM ;
MUFSON, EJ .
JOURNAL OF NEUROSCIENCE RESEARCH, 1990, 27 (04) :595-611